Clinical Trials Directory

Trials / Completed

CompletedNCT02164604

Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease

Intravitreal Ranibizumab to Treat Retinopathy of Prematurity Stage 3 Plus Disease

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Kantonsspital Aarau · Academic / Other
Sex
All
Age
32 Weeks – 40 Weeks
Healthy volunteers
Not accepted

Summary

Retinopathy of prematurity (ROP) is a neovascular retinal disorder of premature born children, characterized by the development of retinal neovascularisation, macular dragging and eventually retinal detachment. ROP is a leading cause for childhood blindness, especially in developing countries. Vascular endothelial growth factor (VEGF) plays an important role in the development of the disease. Recently, the BEAT ROP study tested the efficacy of intravitreal bevacizumab for stage 3 plus ROP in a prospective, controlled, randomized, stratified, multicenter trial. Authors found that bevacizumab showed a significant benefit for Zone I but not Zone II disease, with continuation of peripheral retinal vessel growths after treatment. The authors also concluded that safety could not be assessed due to the small sample size. Other authors raised concerns regarding the results of the BEAT ROP study and the safety of bevacizumab. The investigators suspected a better safety profile for ranibizumab to treat stage 3 plus ROP. Here we present the outcome of 6 eyes with ROP stage 3 plus treated with a single injection of ranibizumab.

Detailed description

The outcome of six eyes with ROP stage 3 plus treated with one single intravitreal injection of ranibizumab is presented. Safety issues and side affects are discussed. Follow up was 6 months.

Conditions

Interventions

TypeNameDescription
DRUGintravitreal injection of 0.03ml ranibizumab

Timeline

Start date
2011-01-01
Primary completion
2013-10-01
Completion
2013-10-01
First posted
2014-06-16
Last updated
2014-06-16

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT02164604. Inclusion in this directory is not an endorsement.